KN063

KN063 is an investigational biologic candidate being developed by Suzhou Alphamab Co., Ltd. for the treatment of metabolic diseases. It is part of the company's innovation pipeline, which typically focuses on the development of single-domain antibodies (sdAb), multi-specific antibodies, and fusion proteins using proprietary protein engineering platforms. As of current public disclosures, the specific molecular target and mechanism of action for KN063 remain proprietary and have not been released. The drug is in the early stages of development, appearing primarily on the developer's internal pipeline listings for metabolic indications.